Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 96

Sort by

Sort Order Select

Journal Articles

Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.

Blood (2025) 146 (Supplement 1): 921.

https://doi.org/10.1182/blood-2025-921

Published: 2025

Journal Articles

Monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy

Blood (2025) 146 (Supplement 1): 582.

https://doi.org/10.1182/blood-2025-582

Published: 2025

Journal Articles

Multi-proteomic analyses provide evidence for origin of a co-existing serum monoclonal gammopathy in CLL/MBL

Blood (2025) 146 (Supplement 1): 7408.

https://doi.org/10.1182/blood-2025-7408

Published: 2025

Journal Articles

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies

Blood (2025) 146 (Supplement 1): 403.

https://doi.org/10.1182/blood-2025-403

Published: 2025

Journal Articles

Risk factors and prevalence of monoclonal gammopathy of undetermined significance (MGUS) by duffy genotype

Lauren Merz, Sabine Allam, Sungjae Kim, Jean-Baptiste Alberge, Jacqueline Perry, David Lee, Katherine Padgett, Julia Colchie, Omar Nadeem, Irene Ghobrial, Paul Richardson

Blood (2025) 146 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2025-4578

Published: 2025

Journal Articles

The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial

Blood (2025) 146 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2025-1033

Published: 2025

Journal Articles

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Blood (2025) 146 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2025-1027

Published: 2025

Journal Articles

Bone marrow spatial architecture predicts response duration in smoldering multiple myeloma patients receiving checkpoint inhibitor therapy

Yoshinobu Konishi, Giuseppe Tarantino, Yiwen He, Romanos Sklavenitis-Pistofidis, Sujal Shah, Ruben Carrasco, Scott Rodig, Jon Aster, Gad Getz, David Liu, Irene Ghobrial

Blood (2025) 146 (Supplement 1): 5702.

https://doi.org/10.1182/blood-2025-5702

Published: 2025

Journal Articles

Identification of persister cells and evolution of tumor clones during immunotherapy and at minimal residual disease timepoints decoded by single-cell whole-genome sequencing in multiple myeloma

Blood (2025) 146 (Supplement 1): 3930.

https://doi.org/10.1182/blood-2025-3930

Published: 2025

Journal Articles

Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy

Blood (2025) 146 (Supplement 1): 3921.

https://doi.org/10.1182/blood-2025-3921

Published: 2025

Journal Articles

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V. Kostopoulos, Romanos Sklavenitis-Pistofidis, Febe Smits, Carmen Roncal, Michelle Aranha, David Zihala, Michaela Machu, Nikolaos Tsakirakis, Panagiotis Bakouros, Ourania Tsitsilonis, Eirini Solia, Cristina Moreno, Catarina Maia, Esperanza Martin-Sanchez, José J. Perez, Cristina Encinas, Rafael Rios Tamayo, Albert Oriol, María-Jesús Blanchard, Felipe de Arriba, Esther González García, Sunil Lakhwani, Anna Sureda Balarí, Valentin Cabanas Perianes, Fernando Escalante Barrigón, Estrella Carrillo-Cruz, Albert Pérez-Montaña, Enrique Ocio, Joan Bargay, Alberto Orfao, Tomas Jelinek, Irene Ghobrial, Tuna Mutis, Sonja Zweegman, Evangelos Terpos, Efstathios Kastritis, Joaquin Martinez-Lopez, Juan-Jose Lahuerta Palacios, Carlos Fernandez de Larrea, Laura Rosiñol, Joan Batista Blade Creixenti, Paula Rodriguez-Otero, María-Victoria Mateos, Jesus San-Miguel, Maria Teresa Cedena Romero, Noemí Puig, Bruno Paiva

Blood (2025) 146 (Supplement 1): 365.

https://doi.org/10.1182/blood-2025-365

Published: 2025

Journal Articles

Characterization of the plasma proteome of multiple myeloma and its precursor conditions and identification of a prognostic high-risk signature of progression

Blood (2025) 146 (Supplement 1): 2168.

https://doi.org/10.1182/blood-2025-2168

Published: 2025

Journal Articles

Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma

Blood (2025) 146 (Supplement 1): 1533.

https://doi.org/10.1182/blood-2025-1533

Published: 2025

Journal Articles

Spatial profiling of the bone marrow microenvironment in patients with IgM gammopathies reveals a T cell–Enriched tumor niche associated with asymptomatic waldenstrom macroglobulinemia progression

David Cordas Dos Santos, Kane Foster, Daniel Heilpern-Mallory, Sophia Schroeder, Minhua Su, Vidhi Patel, Catherine Tobia, Mohammed Rahman, Jacqueline Perry, Daniel Zangrando, Nina Lane, Yoshinobu Konishi, Steven Treon, Gad Getz, Irene Ghobrial

Blood (2025) 146 (Supplement 1): 3559.

https://doi.org/10.1182/blood-2025-3559

Published: 2025

Journal Articles

Landscape Assessment of the Perceptions of Distress and Symptom Burden in Patients with Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Multiple Myeloma (SMM)

Elizabeth K. O'Donnell, Jennifer Carroll, Jacqueline Perry, Katherine Padgett, Vidhi Patel, Omar Nadeem, Areej El-Jawahri, Irene Ghobrial, Catherine R. Marinac

Blood (2024) 144 (Supplement 1): 6872.

https://doi.org/10.1182/blood-2024-201747

Published: 2024

Journal Articles

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 3360.

https://doi.org/10.1182/blood-2024-202653

Published: 2024

Journal Articles

Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis

Blood (2024) 144 (Supplement 1): 3279.

https://doi.org/10.1182/blood-2024-203937

Published: 2024

Journal Articles

Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression

Blood (2024) 144 (Supplement 1): 1903.

https://doi.org/10.1182/blood-2024-209286

Published: 2024

Journal Articles

Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Blood (2024) 144 (Supplement 1): 4984.

https://doi.org/10.1182/blood-2024-194368

Published: 2024

Journal Articles

Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies

Rosa Toenges, Jean-Baptiste Alberge, Francesco Corrado, Nayda Bidikian, David M. Cordas Dos Santos, Ankit K. Dutta, Elizabeth D. Lightbody, Romanos Sklavenitis Pistofidis, Adam S. Sperling, Kenneth C. Anderson, Shonali Midha, Yuxin Liu, Jacob P. Laubach, Eric L. Smith, Nikhil C. Munshi, Omar Nadeem, Irene Ghobrial, Gad Getz

Blood (2024) 144 (Supplement 1): 492.

https://doi.org/10.1182/blood-2024-204132

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.

Monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy

Multi-proteomic analyses provide evidence for origin of a co-existing serum monoclonal gammopathy in CLL/MBL

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies

Risk factors and prevalence of monoclonal gammopathy of undetermined significance (MGUS) by duffy genotype

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Bone marrow spatial architecture predicts response duration in smoldering multiple myeloma patients receiving checkpoint inhibitor therapy

Identification of persister cells and evolution of tumor clones during immunotherapy and at minimal residual disease timepoints decoded by single-cell whole-genome sequencing in multiple myeloma

Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Characterization of the plasma proteome of multiple myeloma and its precursor conditions and identification of a prognostic high-risk signature of progression

Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma

Spatial profiling of the bone marrow microenvironment in patients with IgM gammopathies reveals a T cell–Enriched tumor niche associated with asymptomatic waldenstrom macroglobulinemia progression

Landscape Assessment of the Perceptions of Distress and Symptom Burden in Patients with Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Multiple Myeloma (SMM)

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis

Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression

Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only